|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||15.53 - 15.53|
|52 Week Range||14.56 - 17.95|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||27.78|
|Forward Dividend & Yield||0.47 (3.11%)|
|Ex-Dividend Date||Sep 29, 2022|
|1y Target Est||N/A|
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022.
Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.
Earlier today, Seagen Inc (NASDAQ: FBI) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in metastatic urothelial carcinoma (mUC). Needham says that the results from Cohort K primarily live up to expectations. The management has previously indicated that results from Cohort K could be used to support accelerated approval in the 1L cis-ineligible mUC setting. See the Seagen Analyst Page here.